Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efficient cancer therapy with a nanobody-based conjugate.

Virna Cortez-Retamozo1, Natalija Backmann, Peter D Senter

  • 1Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for Biotechnology, Vrije Universiteit Brussel, Brussels, Belgium.

Cancer Research
|April 17, 2004
PubMed
Summary

Researchers developed a novel nanobody-enzyme conjugate targeting cancer. This conjugate effectively activates anticancer prodrugs at tumor sites, demonstrating potent antitumor activity and potential for new cancer therapeutics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-10 Plays a Critical Role in Mitigating Acute Anaemia Development During African Trypanosome Infection.

Pathogens (Basel, Switzerland)·2025
Same author

Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.

Molecular cancer therapeutics·2025
Same author

Auristatin S: An Auristatin Payload with Improved Tolerability and Modified Bystander Activity.

ACS medicinal chemistry letters·2025
Same author

Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.

Biomolecules·2025
Same author

Evidence for a model of conformational change by the <i>Plasmodium falciparum</i> circumsporozoite protein during sporozoite development in the mosquito host through the use of camelid single-domain antibodies.

Infection and immunity·2025
Same author

Allosteric inhibition of trypanosomatid pyruvate kinases by a camelid single-domain antibody.

eLife·2025

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Nanobodies are small, stable, and soluble single-domain antibody fragments.
  • They function independently of light chains and are highly versatile.

Purpose of the Study:

  • To develop and evaluate a nanobody-enzyme conjugate for targeted cancer therapy.
  • To assess the site-selective activation of an anticancer prodrug using this conjugate.

Main Methods:

  • Identification of a high-affinity nanobody against carcinoembryonic antigen (CEA).
  • Conjugation of the nanobody to Enterobacter cloacae beta-lactamase.
  • In vitro evaluation of prodrug activation on CEA-expressing cancer cells.
  • In vivo studies of biodistribution and antitumor efficacy in tumor xenografts.

Related Experiment Videos

Main Results:

  • A nanobody-beta-lactamase conjugate was successfully generated with high yield and preserved functionality.
  • The conjugate selectively released active chemotherapy from a prodrug at the surface of CEA-expressing cancer cells.
  • In vivo studies showed excellent biodistribution and significant tumor regressions and cures.

Conclusions:

  • Nanobody-based conjugates are effective in site-selective anticancer prodrug activation.
  • These conjugates exhibit potent antitumor activity and favorable biodistribution.
  • Nanobodies represent promising platforms for next-generation cancer therapeutics.